Ascendis Pharma A (ASND) Non-Interest Income (2020 - 2026)
Ascendis Pharma A (ASND) posted Non-Interest Income of $12.0 million for Q1 2026, up 876.36% sequentially from -$1.5 million in Q4 2025, and up 142.93% YoY from $4.9 million in Q1 2025.
Ascendis Pharma A (ASND) Non-Interest Income (2020 - 2026) Analysis & Trends
Ascendis Pharma A has reported Non-Interest Income for 7 years, with the latest figure at $12.0 million in Q1 2026.
- Quarterly Non-Interest Income rose 142.93% year-over-year to $12.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.9 million (up 290.25% YoY) and the FY2025 annual result came in at -$19.0 million, down 164.8% from the prior year.
- Non-Interest Income climbed to $12.0 million in Q1 2026 per ASND's latest filing, from -$1.5 million in the prior quarter.
- Over five years, Non-Interest Income peaked at $228.6 million in Q1 2023 and troughed at -$28.0 million in Q1 2025.
- A 5-year average of $38.3 million and a median of $12.0 million in 2026 frame the typical range for Non-Interest Income.
- The sharpest annual moves came in 2023 and 2025: Non-Interest Income surged 213.92% in 2023, then sank 295.71% in 2025.
- Over 5 years, Non-Interest Income stood at $57.1 million in 2022, then slumped by 82.09% to $10.2 million in 2023, then sank by 52.22% to $4.9 million in 2024, then plunged by 131.63% to -$1.5 million in 2025, then jumped by 876.36% to $12.0 million in 2026.
- According to Business Quant data, Non-Interest Income over the past three periods registered $12.0 million, -$1.5 million, and $8.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Interest Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Ascendis Pharma A | 15.40 Bn | 14.73 Bn | 268.20 Mn | 12.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.00 Mn |
| Dec 31, 2025 | -1.55 Mn |
| Sep 30, 2025 | 8.77 Mn |
| Jun 30, 2025 | 4.64 Mn |
| Mar 31, 2025 | -27.96 Mn |
| Dec 31, 2024 | 4.89 Mn |
| Sep 30, 2024 | 4.80 Mn |
| Jun 30, 2024 | 5.73 Mn |
| Mar 31, 2024 | 14.29 Mn |
| Dec 31, 2023 | 10.23 Mn |
| Sep 30, 2023 | 32.60 Mn |
| Jun 30, 2023 | 59.73 Mn |
| Mar 31, 2023 | 228.58 Mn |
| Dec 31, 2022 | 57.12 Mn |
| Sep 30, 2022 | 89.13 Mn |
| Jun 30, 2022 | 76.04 Mn |
| Mar 31, 2022 | 72.81 Mn |
| Dec 31, 2021 | 35.88 Mn |
| Sep 30, 2021 | 50.61 Mn |
| Jun 30, 2021 | 62.06 Mn |